about
Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular systemElabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionModulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonistBone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertensionHepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.Cardiac action of the first G protein biased small molecule apelin agonist.Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of Portopulmonary HypertensionGrowth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertensionA novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertensionIn Search of the Second Hit in Pulmonary Arterial HypertensionApelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivoInternational Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide LigandACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
P50
Q26823618-B2CB4ED4-1F85-46BE-B5AA-AF729EA806D9Q30032666-06638290-7CC9-4AD5-8340-5FE5AED5C606Q34889050-5C92AA81-0F24-4674-9168-543C95982EE2Q35161744-840116FE-4C37-4AE3-938C-E39927E94025Q36185917-367D38A2-C7C0-4459-9F19-6A3D2E6CCC29Q36516808-D0BBD78C-3C29-43A8-BAD2-A989C631C72DQ37670483-C1DF536D-6F5C-4C19-A211-5FC16D77AE8EQ39541969-59DEEA19-99E3-4481-ABE3-60E9481382D6Q57469996-37180AE6-237F-4491-807C-ECE1928C9760Q63916376-55EB462A-4D17-4FE0-92FF-D8D545F31A4DQ64089771-7F4504F6-3E11-4881-AA0C-5D2E6005B543Q90864092-3F3AFD06-C93B-4AC6-BEBD-DEC579B18DA9Q92552447-ECA9D3C6-8652-4254-AD74-A92BD11BFD67Q93161720-ACF89511-584D-427F-A261-69125DE4AA0CQ94670429-6FE7C6D5-E119-455C-9506-BBD5E32CE3BF
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Peiran Yang
@ast
Peiran Yang
@en
Peiran Yang
@en-gb
Peiran Yang
@es
Peiran Yang
@nl
Peiran Yang
@sl
type
label
Peiran Yang
@ast
Peiran Yang
@en
Peiran Yang
@en-gb
Peiran Yang
@es
Peiran Yang
@nl
Peiran Yang
@sl
prefLabel
Peiran Yang
@ast
Peiran Yang
@en
Peiran Yang
@en-gb
Peiran Yang
@es
Peiran Yang
@nl
Peiran Yang
@sl
P106
P31
P496
0000-0002-4635-1215